Galectin Therapeutics (NASDAQ:GALT) Director Harold Shlevin Sells 24,499 Shares

Galectin Therapeutics Inc. (NASDAQ:GALT) Director Harold Shlevin sold 24,499 shares of the firm’s stock in a transaction dated Wednesday, December 17th. The shares were sold at an average price of $7.04, for a total transaction of $172,472.96. Following the completion of the sale, the director owned 6,500 shares of the company’s stock, valued at $45,760. The trade was a 79.03% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this link.

Galectin Therapeutics Price Performance

Shares of GALT stock traded down $1.78 during trading hours on Friday, reaching $4.38. 4,104,407 shares of the company were exchanged, compared to its average volume of 417,051. Galectin Therapeutics Inc. has a fifty-two week low of $0.73 and a fifty-two week high of $7.13. The stock’s fifty day moving average is $5.57 and its two-hundred day moving average is $4.15. The company has a market cap of $282.38 million, a price-to-earnings ratio of -7.42 and a beta of 0.95.

Galectin Therapeutics (NASDAQ:GALT) last issued its quarterly earnings results on Friday, November 14th. The company reported ($0.13) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.11) by ($0.02). On average, research analysts anticipate that Galectin Therapeutics Inc. will post -0.73 earnings per share for the current year.

Key Headlines Impacting Galectin Therapeutics

Here are the key news stories impacting Galectin Therapeutics this week:

• Positive Sentiment: FDA written response aligns with the company on the proposed patient population for a registration trial of belapectin and the company will pursue a follow‑up Type C meeting to finalize trial design; management says new biomarker data will be presented. This reduces some regulatory uncertainty for the lead program. Galectin Therapeutics Provides Regulatory Update
• Positive Sentiment: Galectin secured a $10M unsecured, convertible line of credit from its chairman and extended maturities on related notes, which management says funds operations into at least March 2027 — a near‑term liquidity buffer while belapectin development continues. Regulatory update & financing
• Neutral Sentiment: Technically, the stock recently crossed above its 200‑day moving average — a bullish technical sign for some traders, but not a fundamental change. Shares Cross Above 200-Day Moving Average
• Negative Sentiment: Significant insider selling: multiple insiders (CEO Joel Lewis, Director Harold H. Shlevin, CMO Khurram Jamil) sold large blocks of stock on Dec. 16–17 at prices in the $6.66–$7.06 range — and a major shareholder (Fund L.P. 10X) also sold ~30,681 shares. The concentrated selling likely pressured the share price despite the regulatory/financing news. Insider Selling: Galectin Therapeutics
• Negative Sentiment: While HC Wainwright maintained a Buy and raised its price target to $11 (from $6), analyst optimism can be slower to offset immediate selling pressure from insiders and short‑term traders. HC Wainwright maintains Buy, raises target

Wall Street Analysts Forecast Growth

GALT has been the topic of several recent research reports. HC Wainwright raised their price target on Galectin Therapeutics from $6.00 to $11.00 and gave the company a “buy” rating in a report on Wednesday. Weiss Ratings restated a “sell (d-)” rating on shares of Galectin Therapeutics in a research report on Wednesday, October 8th. One research analyst has rated the stock with a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus price target of $11.00.

Institutional Investors Weigh In On Galectin Therapeutics

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Hudson Bay Capital Management LP bought a new stake in Galectin Therapeutics in the 3rd quarter valued at $63,000. Vivaldi Capital Management LP raised its stake in shares of Galectin Therapeutics by 48.3% in the 3rd quarter. Vivaldi Capital Management LP now owns 255,752 shares of the company’s stock valued at $1,083,000 after purchasing an additional 83,309 shares during the period. Qube Research & Technologies Ltd raised its stake in shares of Galectin Therapeutics by 290.9% in the 3rd quarter. Qube Research & Technologies Ltd now owns 60,867 shares of the company’s stock valued at $258,000 after purchasing an additional 45,297 shares during the period. Lido Advisors LLC bought a new stake in shares of Galectin Therapeutics in the third quarter valued at about $154,000. Finally, Bank of America Corp DE boosted its position in shares of Galectin Therapeutics by 129.4% during the third quarter. Bank of America Corp DE now owns 25,327 shares of the company’s stock worth $107,000 after buying an additional 14,285 shares during the period. 11.68% of the stock is currently owned by institutional investors and hedge funds.

Galectin Therapeutics Company Profile

Galectin Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of novel therapies that target galectin proteins, which are implicated in fibrotic, inflammatory and malignant diseases. The company’s lead product candidate, belapectin (formerly GR-MD-02), is a galectin-3 inhibitor being evaluated in Phase 2 clinical trials for nonalcoholic steatohepatitis (NASH) with cirrhosis. In addition to its core pipeline in fibrotic liver disease, Galectin Therapeutics continues to explore the potential of its galectin inhibitors in oncology and other indications driven by abnormal tissue remodeling.

Founded in 2000, the company is headquartered in Norcross, Georgia, where it oversees discovery research, preclinical studies and clinical trial coordination.